AviadoBio Joins Kadans Science Partner at Canary Wharf Innovation Centre

Innovative New Tenant at Canary Wharf

Kadans Science Partner has announced AviadoBio as the newest addition to their tenant roster at the Canary Wharf Life Sciences Innovation Centre. AviadoBio is a leading-edge gene therapy company that focuses on the development and delivery of transformative medicines for neurodegenerative disorders. The company is set to establish its laboratory and office presence at the Innovation Centre, further enhancing the growing life science ecosystem in the area.

AviadoBio’s New Laboratory and Office Space

AviadoBio will be operational at Kadans’ London Innovation Centre, following the recent completion of their wet-lab Innovation Centre at levels four and five at 20 Water Street. This new office and laboratory space, designed with dynamic and creative interior design elements, will provide the perfect setting for AviadoBio’s team to innovate and develop transformative gene therapies. The company will be joining the Kadans’ growing European ecosystem of over 450 tenants.

Comments from AviadoBio and Kadans Science Partner

Lisa Deschamps, CEO of AviadoBio, expressed her excitement about the new partnership with Kadans and the state-of-the-art facilities at the Innovation Centre at Canary Wharf. Claudia Tripp, commercial asset manager at Kadans Science Partner, also shared her satisfaction with securing AviadoBio as a tenant so soon after the Innovation Centre’s opening, emphasizing the demand for flexible, high-quality wet lab facilities.

Facilities at the Innovation Centre

The Innovation Centre boasts 40,000 sq ft of fully fitted, flexible, wet-labs. These labs range from bespoke 250 sq ft to over 2,000 sq ft, with tenants having the option of renting a bench in a shared lab, or taking their own private lab. This flexibility is aimed at accommodating a range of tenants, from start-ups to early-stage companies, allowing them to grow within the Canary Wharf ecosystem.

Future Development at Canary Wharf

In line with the growth of the life sciences community at Canary Wharf, Kadans and Canary Wharf Group are advancing a joint venture to develop an 823,000 sq ft commercial health and life sciences building on the North Quay site. This building, anticipated to be the largest in Europe, is expected to be completed by 2027, further solidifying Canary Wharf’s position as a hub for health and life sciences.